2014 旭富企業社會責任報告

__________________________________________________________ 1

CSR _______________________________________________________ 3

1.

1.1. ______________________________________________________ 4

1.2 __________________________________________________ 5

1.3 ________________________________________________________ 6

2.

2.1 _____________________________________________ 7

2.2 ________________________________________________ 21

2.3 ______________________________________________________ 27

2.4 _________________________________________ 30

2.5 ___________________________________________ 40

2.6 ______________________________________________________ 48

2.7 ______________________________________________________ 49

3.

3.1 ________________________________________________ 51

3.2. ___________________________________________ 53

3.3. ______________________________________________________ 57

3.4 ______________________________________________________ 64

4.

4.1. ______________________________________________________ 66

4.2 ________________________________________________ 77

4.3 ______________________________________________________ 82

4.4 ____________________________________________________ 84

4.5. ________________________________________________ 89

1

1962 Rachel Carson

WBCSD

Ray C. Anderson

2015

3 3

7

doing good while

doing well

Thomas L. Friedman

3 COD

2

PPON

4CCustomers

CoworkersCommunityCorporate

Customers

Coworkers

Community

Corporate

2014~2015

CSR

3

CSR

1987

1.

4

1.1.

2014

CSR 2013

2014~5

(Global Reporting InitiativeGRI)(GRI G4 Guidelines)

GRI G4

CSR

1.

5

1.2

GRI G4 Core

GRI G4

2016 7

2014 1 1 2015 12 31 2014

2015

2014 1 1 2015 12

31

()

2014 10 100%

1.

6

1.3

CSR

33856 16 186-2

+886-3-354-3133

+886-3-354-3483

Corporate Website

http://www.sci-pharmtech.com.tw

CSR Website

http://www.sci-pharmtech.com.tw/csr/cmp.html

ext.210

michele.seah@sci-

pharmtech.com.tw

ext.415

wcchou@sci-

pharmtech.com.tw

ext.710

deiter@sci-

pharmtech.com.tw

ext.413

ricky.liu0883@sci-

pharmtech.com.tw

http://www.sci-pharmtech.com.tw/http://www.sci-pharmtech.com.tw/csr/cmp.htmlmailto:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]:[email protected]

2.

7

2.1

2.1.1

Siegfried 1987

1

1

2004

/

09/18/1987

SCI Pharmtech, Inc.

16 186 2

751,213,360

1,810,500,869

217

( 2015.12.31 )

2.

8

( 2015.12.31 )

Yushan Holding

Universal Ltd.

USD 12,485

100%

NTD371,000

100%

2.

9

1987 09 SIEGFRIED

1991 03

1996 04 SIEGFRIED 100%

1999 11 ISO 14001

2001 04 80%

2001 10 ISO 9001 2000

2002 05

2002 07

2002 08

2003 06

2004 01 4119

2004 06

2005 11 FDA

2008 06

2010 06 OHSAS 18001:2007

2011 03 EDQM

2013 01 FDA 2

2013 03

2013 06

2013 08

2014 10

2015 04 FDA 3

2015 10 9

2.

10

2.1.2

2015

2.

11

2016

2.

12

-

-

-

-

-

-

-

-

-

-

-

-

- OHSAS18001

-

- cGMPISO 9001ISO 14001 OHSAS198001

- GMP

-

-

-

-

-

-

-

-

-

-

-

- SOP

-

2.

13

-

-

-

- CGMP

-

-

-

-

-

-

-

-

- ISO14001

-

-

-

- :

- cGMP

-

-

-

-

-

-

-

-

-

2.

14

ISO 9001 / ISO 14001 / GMP / OHSAS 18001

2.

15

()

2013 8 (

)

2.

16

2.

17

2013 5 30

2.

18

CSR

2.

19

2.1.3

2013 3

12,000 58 696,000

6,000 600,000

104 11

10

()

2013 3 580,000

2015 3 220,104

2015 4 495,896

1,296,000

1. 105 1

%

220,104 220,104 100.00

495,896 495,896 100.00

716,000 716,000 100.00

2.

20

2.

(a)

104 3

371,000

(b)

2.

21

2.2

87%

API

Raw Material

Intermediate

Products before API

API

Treatable ingredient

Formulation

Upstream

Midstream

Downstream

2.

22

VA

Di-VANa

Propafenone

Methylphenidate

Duloxetine

Cyclophosphamide

Loxoprofen

Articaine HCl

HOCLQ-sulfate

Brinzolamide

Atomoxetine

Pent-2

PGA

NBE

5-HMT

BOV

(S)-MMAA

HOCLQ

Prop-3

Thiazole acid

S20/38

2.

23

2014 2015

(%) (%)

636,225 42.65 671,158 37.07

323,784 21.70 521,670 28.81

271,348 18.19 383,266 21.17

12,475 0.84 63,488 3.51

248,030 16.62 170,919 9.44

1,491,862 100.00 1,810,501 100.0

54% 40%

6%

2015

2.

24

2.2.1

SDS

2,000,000

SOP WH-002

()

TFDA

CAS no.SCI code no.Lot no.

2014~5

ISO 9001

2001 ISO 9001 2013

2015 FDA

1. GMP / ISO 9001

2.

2.

25

GMP

GMP Good Manufacture Practice

GMP

cGMP Current Good Manufacture Practice

(FDA)FDA

(GMP) 1999

5 (cGMP) 1999 10 21

2000 7

1

cGMP

cGMP

EDQM

GMP

DMF

(Drug Master File, DMF)

DMF

2.

26

2.2.2

(Pentobarbital

Sodium)

(Methylphenidate)

2.

27

2.3

2010 5

2016

2015 1,810,501 36 439,687

373,902 5.17

2015

FDA

1,038

1,263 1,290

1,492

1,836

106 238 194

335 451

2011 2012 2013 2014 2015

2.

28

2013 2014 2015

1,292,734 1,491,862 1,810,501

895,753 1,012,209 1,155,449

396,981 479,353 655,052

58,570 70,530 115,792

100,464 77,338 64,182

32,088 36,119 35,391

205,859 295,366 439,687

12,079 39,728 11,803

193,780 335,094 451,490

33,842 70,255 77,588

159,938 264,839 373,902

3,016 2,768 8,926

162,954 262,071 364,976

159,938 264,839 373,902

162,954 262,071 364,976

2.

29

()

304,422 2015

825,442 2015

273,134 2015

2,200 2015

20,541 2015

9,456 2015

43,043 2015

2013 2014 2015

32,088 36,119 35,391

1,292,734 1,491,862 1,810,501

2.48% 2.42% 1.95%

2.

30

2.4

2.4.1.

AA1000 SES

5

7

NGO

2.

31

1./

2.

3./

4.(/)

1.

2.

3.

4.

5.

1.

2.

3.

1.

2.

1.

2.

3.

4./

1.

2.

3.

/

1.

2.

3.

4./

5.

1.

2.

3.

4.

5.

NGO/NPO

1.

2.

3.

4.

5.

6.

7./

1.

2.

3.

4.

5.

1.

2.

1.

2.

1.

2./

3.

1.

2.

3.

4.

2.

32

2014~5

2014 3 2015 5

8

2014 21 2

08/08/2014

2014

-

Thionyl chloride(SOCl2)

SOCl2

10/16/2014

2.

33

2014

RD 25DCMT

IBC

IBC

12/05/2014

2015

1.

2. 1000L

IBC

03/30/2015

2015 DBS

04/03/2015

2015 02/04 Sump

sump

05/11/2015

2015

SCR1101

10/06/2015

2015 6T

Sump

1.

2.

12/31/2015

2.

34

2.4.2

2014~5

GRI G4

46

11

21

33 GRI G4

2.

35

(a)

CSR

(b)

-

-

-

(c)

-

-

-CSR

(d)

(e)

CSR

2.

36

2.

37

1 2 6

4 3 7

17 5 8

18 9 13

19 10 14

20 11 16

21 12 25

39 15 26

42 22 30

43 23 31

46 24 32

27 33

28 40

29 45

34

35

36

37

38

41

44

2.

38

1

2.3, 4.1.5

4

3.3.1

17

4.1.2, 4.1.5

18

4.1.5

19

4.2

20

4.1.4

21

4.1.2

39

2.6

42

2.2.1

43

2.2.1, 4.3.1

46

2.6

2.

39

2.4.3

1.

2.

3.

4. CPHI

2.

40

2.5

GCHS-GCHPLC

IRDSCTGALaser Particle size analyzer

cGMP 2001 10 ISO 9001:2000

2.

41

2.

42

GMP

SOP

2.

43

ERP

2.

44

6%

PGA

FDA EDQM

GMP

10%

10

10%

HOCLQ Sulfate 21.52%

PGA 17.14%

VA 10.64%

LPF.Na 7.48%

Di-VANa 5.41%

2015

2.

45

1996

2015 20%

90%

15%

2% 3,000

2015 228 145

2.

46

2-3

2015 1 18,142

2,489

2015 9,456

2015 1,400

2015 12

2% 2400

2.

47

2

2.

48

2.6

DMF

GMP

2014-2015 2012 7

23

103 5 27 100,000

103

12 30

1 2013

5 27 10

2.

49

2.7

8-11 A+

2.

50

GMP

ISO 90012008

ISO 140012004

OHSAS180012007

GMP

3.

51

3.1

1.

---

2.

3.

4.

5.

6.

3.

52

ISO 14001OHSAS 18001

PDCA

2014~2015

1.

2. 4.5 Kg COD/M3d

700 CMD

3. /

4.

5. VOC

6.

2014~2015

1. 2014~2015 85%

2. 2013 2017

3.

02/04/03/03B/11/

21/22/23/24

4. 2014 9 2015 12

5. 0600~

1200

6.

8 / 115

3.

53

3.2.

3.2.1. (ODS)

25%

24

()

2013

2014 3 2015 5

0600~1200

25%

3.

54

3.2.2.

4000

18

64

2015

2013 33%

T5 LED

3.

55

()

()

*

(/)

2013 17,731,894 2,438 0.0729

2014 17,778,000 2,530 0.0839

2015 18,619,600 2,610 0.0972 *

2013

NT$ 230K

6

4.98 3.29

2014

28% 18%

40%

NT$ 175K 0.75kW/hp

2.9

2015

1.

LED

2.

1.

100W

2. 24

1.

LED

40W

2. 16

1.NT$ 44K

2.NT$ 1,088K

1. 150 3060

2.78

2 96kW 8

2.78

3.

56

(/) CO2e*(kg/) CO2(kg)

2013 59,460 0.522 31,038

2014 60,320 0.521 31,426

2015 63,072 0.521 32,861

*

2014

()(

) 2015

2014 2015

(kgCO2e) 8,159,090 8,272,217

(kgCO2e) 9,457,896 9,905,627

(kgCO2e) 17,616,986 18,177,844

(kgCO2e/) 11.81 10.04

1

6.0.1

2 2013 0.522

3.

57

3.3.

3.3.1.

cGMP

3.

58

2014 2015

93.2% 4.8%

28.2% 9.1%

33.5% 0.2%

6.9% 3.2% 7.4%

()()

Mitsubishi(DAISO)

()

MSSA

()

()

()()

3.

59

API

24

5

2014 2015

1,586Kg 1,690Kg 202,883Kg

217,038 Kg 82,139Kg 131,877Kg

GMP ()

(LDPE HDPE )

()(HDPE )(

)

3.

60

3.3.2.

(+)

2014 15.1 2015 14.9

35%

(2014 2015

2013 20~40%)

(m3)

(m3)

()

/

(/m3)

2013 165,000 55,000 838,053 5.08

2014 151,000 52,000 927,000 6.13

2015 149,000 52,000 1,113,000 7.47

3.

61

3.3.3.

/- M01

M02 M03

()

TSP(Ton) SOx(Ton) NOx(Ton) VOCs(Ton)

2013 1.783 18.915 15.054 38.872

2014 1.741 17.986 13.268 37.565

2015 2.154 21.338 13.431 35.62

3.

62

SBR

550 CMD

2010

2011

UASB2012

2015 2016

UASB SBR

900 CMD

2013 2014 2015

140515 128219

118001

()

3.

63

2014 3707.59

4423.47 1662.59 2015 2882.5

4343.46 1982.1 2014~2015

2.44% 6.17%

12.47%

60.92%

18.00%

2014

1.34% 6.82%

26.72%

56.80%

8.33%

2015

3.

64

/

1. 35%()

2./

3.

65

3.4

3.4.1.

2014 74.8 2015 71.6

(

40.71%)//

( 37.15%)

( 11.45%)

//

( 30 2013 )(

9.69%)

( 1%)

41%

11% 10%

37%

1%

2014~5

4.

66

4.1.

4.1.1.

A.

B.

16

C.

D.

4.

67

A.

B. SOP

C.

D. AED

E.

F.

G.

H.

I.

J.

4.

68

4.1.2.

16

2015 221 31

10

0

50

100

21-30 31-40 41-50 51-60 61-70

51

77

35 18

2

7

14

10

7

0%20%

40%60%

/

3.62%

12.67%

54.75%

12.67%

16.29%

4.

69

2015 25 13 20

20-40 22

3

2015 17 3

3 5.42%

5

7 5

21-30 31-40 41-50 51-60

14

8

3 0

0

0

0

0

4

1

20

21-30 31-40 41-50

6 5 3

0 1 2

0

3

0

14

13

3

1

4.

70

4.1.3.

9

1 8

4.

71

4.1.4.

2015 11,761

6,867 364 477 2015

125 2015

197,519

7987 7932 10031

11761

113 126

136

125

2012 2013 2014 2015

http://10.10.10.253/csr/labor_issue_statement.html##

4.

72

60

10

15

1

0 50 100

2015 60 15 75 10 1 11

GMP

100%

4.

73

HAZMAT Team HAZMAT Team

AED & CPR

4.

74

4.1.5.

1 2 30,000 20,008

(

)

4.

75

5%

() 6%

()

510152025

7

9~11

4.

76

2015 2 8

1

1.

2.

A.

B.

C.

4.

77

4.2

SOP

4.

78

5

10

50%

PDCA

100%

4.

79

5.16 5.16 7.74

33.54

69.66

54.18

2013 2014 2015

(SR) (FR)

4.

80

(F.R.):

/

(S.R.):

/

X

2015

10 (Framingham) 20

3 (2~3 /)

19 15

72%

14%

14%

4.

81

1. 8

A. 08:30-17:15

12:30-13:15

B. 08:30-16:30

16:30-24:30

24:30-08:30

2.

12 46

4.

82

4.3

4.3.1

2% 1%

(Quality)/

(Label/ Packaging)(Lead time)(Delivery)(Services)

(Documentation)(Safety)(Competitiveness)(Repeated

Order)

(DMF)/

0.00.51.01.52.02.53.03.54.04.55.0

Period: July 2010 ~ June 2011





4.

83

4.3.2

4.

84

4.4

4.4.1

IBC 53

PE

Reduce/Reuse/Recycle

4.

85

75

2015

240 43% 19% 8%

5% 6% 13% 6%

43%

19%

8%

5%

6%

13%

6%

4.

86

60%

33% 47% 3.5% 7.5% 0.3% 8.7%

33%

47%

4%

7%

9%

4.

87

4.4.2

ISO 9001ISO 14001OHSAS 18001 cGMP

SOP

SCI-101.13 Raw Material and Packaging Material Supplier Qualification

SCI-308.09 Assessment of Raw Materials

Supplier's EHS Management System

4.

88

30

()

(COA) MSDS

REACH

2013

4.

89

4.5.

1.

2. 2015 150

3. 2015 20

4. 2015

15

5. 2015

35

1. 2015

2.

3.

4.

2015

4.

90

1. 2015 364,976

2. 2015 43,043

3. 221

2010 2011 2012 2013 2014 2015

2 0 2 2 1 0

0 2 0 0 0 0

4 0 0 2 2 0

6 2 2 4 3 0

2014

GRI G4

G4

General Standard Disclosures

Strategy and Analysis

G4-1()

a. CEO

G4-2 a. -- --

Organizational Profile

G4-3() a. 2.1.1 7

G4-4() a. 2.2 22

G4-5() a. 2.1.1 7

G4-6() a.(

) 2.1.1 7

G4-7() a. 2.1.1 8

G4-8() a./

2.2 23

G4-9() a. 2.1.1 7

G4-10()

a.

b.

c.

d.

e.

f.

4.1.2 68~69

G4-11() a. 4.1.5 74

G4-12() a. 3.3.1 58

G4-13() a. 2.1.3 19

G4-14() a. 2.1.2 14

G4-15() a.

-- --

G4-16() a.

2.4.3 39

GRI G4

G4

Identified Material Aspects and Boundaries

G4-17()

a.

b.

2.3 27~28

G4-18() a.

b. 2.4.2 34~35

G4-19() a. 2.4.2 36~37

G4-20() a. 2.4.2 38

G4-21() a. 2.4.2 38

G4-22() a. 1.2 5

G4-23() a. 1.2 5

Stakeholder Engagement

G4-24() a. 2.4.1 31

G4-25() a. 2.4.1 30

G4-26() a.

2.4.1 32

G4-27()

a.

2.4.1 32~33

Report Profile

G4-28() a. 1.2 5

G4-29() a. 1.1 4

G4-30() a. 1.1 4

G4-31() a. 1.3 6

G4-32()

a.

b. GRI

c. //GRI

/

1.2 5

G4-33()

a. /

b. /

/

c. /

d.

1.2 5

GRI G4

G4

Governance

G4-34() a.

2.1.2 17

G4-35 a.

-- --

G4-36 a.

-- --

G4-37

a.

-- --

G4-38 a. -- --

G4-39 a. (

) -- --

G4-40 a.

-- --

G4-41 a.

-- --

G4-42

a.

-- --

G4-43 a.

-- --

G4-44

a.

b.

-- --

G4-45

a.

b.

-- --

G4-46 a.

-- --

G4-47 a. -- --

G4-48 a.

-- --

G4-49 a. -- --

GRI G4

G4

G4-50 a.

-- --

G4-51

a.

b.

-- --

G4-52 a.

-- --

G4-53 a.

-- --

G4-54

a.

-- --

G4-55

a.

-- --

Ethics and Integrity

G4-56() a. 2.1.2 15

G4-57 a.

-- --

G4-58 a.

-- --

Specific Standard Disclosures

Disclosures on Management Approach

G4-DMA

a.

b.

c.

2.2.1

2.3

2.5

3.1

3.2.2

3.3.1

4.1.2

4.1.4

4.1.5

4.2

4.5

24

27

40

51

54

57

68

71

74

78

89

GRI G4

G4

Indicators by Aspects

Economic

Economic Performance (OECD)

G4-EC1 2.3 27

G4-EC2 -- --

G4-EC3 4.1.5 74~76

G4-EC4 -- --

Market Presence

G4-EC5 4.1.5 74

G4-EC6 4.1.2 68

Indirect Economic Impacts

G4-EC7 -- --

G4-EC8 -- --

Procurement Practices

G4-EC9 3.3.1 58

Environment

Materials

G4-EN1 3.3.1 58

G4-EN2 3.3.1 59

Energy

G4-EN3 3.2.2 55

G4-EN4 -- --

G4-EN5 -- --

G4-EN6 3.2.2 55

G4-EN7 3.2.2 55~56

Water

G4-EN8 3.3.2 60

G4-EN9 -- --

G4-EN10 3.3.2 60

GRI G4

G4

Biodiversity

G4-EN11

-- --

G4-EN12

-- --

G4-EN13 -- --

G4-EN14

IUCN -- --

Emission

G4-EN15 3.2.2 56

G4-EN16 -- --

G4-EN17 3.2.2 56

G4-EN18 -- --

G4-EN19 3.2.2 56

G4-EN20 (ODS) 3.2.1 53

G4-EN21 3.3.3 61

Effluents and Waste

G4-EN22 3.3.3 62

G4-EN23 3.3.3 63~64

G4-EN24 2.4.1 32~33

G4-EN25 IIIIIIVIII

3.3.3 63

G4-EN26

-- --

Products and Services

G4-EN27 3.3.1 59

G4-EN28 3.3.1 59

Compliance

G4-EN29

2.6 48

Transport

G4-EN30

3.3.3 64

GRI G4

G4

Overall

G4-EN31 3.4.1 65

Supplier Environmental Assessment

G4-EN32 4.4.2 88

G4-EN33 4.4.1 87~88

Environmental Grievance Mechanisms

G4-EN34 2.4.1 32~33

Social

Labor Practices and Decent Work

Employment

G4-LA1 4.1.2 69

G4-LA2 ()

4.1.5 74~75

G4-LA3 4.1.5 76

/ Labor/Management Relations

G4-LA4 4.1.5 76

Occupational Health and Safety

G4-LA5

4.2 78

G4-LA6

4.2 79

G4-LA7 4.2 80

G4-LA8 -- --

Training and Education

G4-LA9 4.1.4 71

G4-LA10

4.1.4 72

G4-LA11 4.1.4 72

Diversity and Equal Opportunity

G4-LA12

4.1.2 68

GRI G4

G4

Equal Remuneration for Women and Men

G4-LA13 4.1.5 74

Supplier Assessment for Labor Practices

G4-LA14 4.4.2 87~88

G4-LA15 4.4.2 87~88

Labor Practices Grievance Mechanisms

G4-LA16 -- --

Human Rights

Investment

G4-HR1 -- --

G4-HR2 4.1.4 72

Non-discrimination

G4-HR3 4.1.5 76

Freedom of Association and Collective Bargaining

G4-HR4

4.1.3 70

Child Labor

G4-HR5

4.1.2 68

Forced or Compulsory Labor

G4-HR6

4.2 81

Security Practices

G4-HR7 4.1.4 72

Indigenous Rights

G4-HR8 4.1.5 76

Assessment

G4-HR9 4.1.1 66

Supplier Human Rights Assessment

G4-HR10 4.4.2 87

G4-HR11 4.1.1 66

GRI G4

G4

Human Rights Grievance Mechanisms

G4-HR12 4.1.5 76

Society

Local Communities

G4-SO1 -- --

G4-SO2 -- --

Anti-corruption

G4-SO3 2.1.2 15

G4-SO4 2.1.2 15

G4-SO5 2.1.2 15

Public Policy

G4-SO6 / -- --

Anti-competitive Behavior

G4-SO7 -- --

Compliance

G4-SO8 2.6 48

Supplier Assessment for Impacts on Society

G4-SO9 4.4.2 87

G4-SO10 4.4.2 87

Grievance Mechanisms for Impacts on Society

G4-SO11 2.4.1 32

Product Responsibility

Customer Health and Safety

G4-PR1 2.2.1 24

G4-PR2

2.2.1 24

Product and Service Labeling

G4-PR3

2.2.1 24

G4-PR4 2.2.1 24

G4-PR5 4.3.1 82

GRI G4

G4

Marketing Communication

G4-PR6 2.2.2 26

G4-PR7

-- --

Customer Privacy

G4-PR8 4.3.2 83

Compliance

G4-PR9 2.6 48

2014 旭富企業社會責任報告

Health & Medicine